Zuneca Pharmaceutical v. Natrapharm
NEW DOCTRINEFacts
The Antecedents: Zuneca Pharmaceutical (Zuneca) has been using the trademark "ZYNAPS" for its drug carbamazepine since 2004. Natrapharm, Inc. (Natrapharm) registered the trademark "ZYNAPSE" for its drug citicoline on September 24, 2007. Both parties admitted that the marks "ZYNAPS" and "ZYNAPSE" are confusingly similar and are used for medicines. Procedural History: Natrapharm filed a complaint against Zuneca for trademark infringement, seeking injunction and damages. The Regional Trial Court (RTC) ruled in favor of Natrapharm, finding Zuneca liable for infringement and enjoining its use of "ZYNAPS." The Court of Appeals (CA) affirmed the RTC's decision. Zuneca appealed to the Supreme Court. The Petition: Zuneca assailed the CA's ruling, arguing that as the prior user in good faith, its rights should prevail over Natrapharm's first-to-file registration. Zuneca also contended that Natrapharm registered "ZYNAPSE" in bad faith. The core of Zuneca's argument was that prior use, not prior registration, should determine ownership.
Issue(s)
Whether the CA erred in affirming the RTC's ruling that the first-to-file trademark registrant in good faith defeats the right of the prior user in good faith. Whether the CA erred in affirming the RTC's finding that Natrapharm was in good faith when it registered the trademark "ZYNAPSE." Whether the CA erred in affirming the RTC's ruling that Zuneca is liable for trademark infringement and thus liable for damages and attorney's fees, and should be enjoined from using "ZYNAPS." Whether the CA erred in affirming the RTC's dismissal of Zuneca's counterclaims. Whether the CA erred in ruling that Zuneca, for failure to register "ZYNAPS" and oppose Natrapharm's application, is barred by laches and deemed to have abandoned its trademark.
Ruling
The Supreme Court partly granted the petition. It affirmed Natrapharm as the lawful registrant of "ZYNAPSE" but set aside the rulings holding Zuneca liable for trademark infringement and damages, and enjoining its use of "ZYNAPS." The Court declared Zuneca as a prior user in good faith, protected under Section 159.1 of the IP Code. The Court also ordered both parties to clearly indicate on their packaging the medical conditions their respective drugs treat and a warning about what they do not treat, and directed the Food and Drug Administration to monitor compliance.
Ratio Decidendi
On Whether the CA erred in affirming the RTC's ruling that the first-to-file trademark registrant in good faith defeats the right of the prior user in good faith: The Court held that while ownership of a mark is acquired through registration under the IP Code, Section 159.1 of the IP Code protects prior users in good faith. This provision states that a registered mark has no effect against a person who, in good faith, was using the mark before the filing date or priority date of the registered mark. Therefore, Zuneca, as a prior user in good faith, is protected and cannot be held liable for infringement for its prior use, despite Natrapharm being the first registrant. The Court clarified that the legislative intent was to shift to a registration-based system but not to completely abandon the protection for prior users in good faith. On Whether the CA erred in affirming the RTC's finding that Natrapharm was in good faith when it registered the trademark "ZYNAPSE": The Court affirmed the lower courts' finding that Natrapharm acted in good faith. Zuneca failed to provide sufficient evidence to prove that Natrapharm had knowledge of "ZYNAPS" prior to registering "ZYNAPSE." Natrapharm presented evidence of its due diligence, including checking databases like the IMS-PPI, IPO, and BFAD, and found no confusingly similar marks. The Court found Zuneca's evidence of potential knowledge through shared conventions and publications insufficient to overcome the presumption of good faith. On Whether the CA erred in affirming the RTC's ruling that Zuneca is liable for trademark infringement and thus liable for damages and attorney's fees, and should be enjoined from using "ZYNAPS": The Court ruled that Zuneca is not liable for trademark infringement. This is because Section 159.1 of the IP Code exempts prior users in good faith from infringement actions. The Court interpreted this provision to mean that a prior user in good faith can continue to use its mark even after the registration of a confusingly similar mark by another, subject to the condition that the right is transferred with the enterprise. Since Zuneca is a prior user in good faith, it cannot be held liable for infringement, and thus the injunction and damages awarded by the lower courts were set aside. On Whether the CA erred in affirming the RTC's dismissal of Zuneca's counterclaims: The Court affirmed the dismissal of Zuneca's counterclaims. Zuneca's counterclaims were based on its claim of ownership as a prior user. However, under the IP Code, ownership is primarily acquired through registration. Since Zuneca failed to register its mark and did not prove Natrapharm's bad faith in registration, it did not acquire the status of an "owner of a registered mark" that could prevent Natrapharm's use or seek cancellation of its registration based on prior use alone. On Whether the CA erred in ruling that Zuneca, for failure to register "ZYNAPS" and oppose Natrapharm's application, is barred by laches and deemed to have abandoned its trademark: The Court found that Zuneca did not abandon its trademark "ZYNAPS" and was not barred by laches. While Zuneca failed to register its mark, it was actively using it. The Court's ruling under Section 159.1 protected Zuneca's right as a prior user in good faith, implying that its continued use, despite lack of registration, was not considered abandonment or subject to laches in this context, especially given the protection afforded by Section 159.1.
Main Doctrine
While ownership of a trademark is acquired through registration under the Intellectual Property Code (IP Code), the rights of a prior user in good faith are protected under Section 159.1 of the IP Code. This means a prior user in good faith can continue to use its mark even after a confusingly similar mark is registered by another, as long as the use was in good faith before the filing or priority date of the registered mark, and the right is transferred with the enterprise. Consequently, such prior users are not liable for trademark infringement for their prior use.